Wired News – Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas

Stock Monitor: Ovid Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Clementia Pharma Inc. (NASDAQ: CMTA). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CMTA as the Company’s latest news hit the wire. On April 20, 2018, the Company announced that it has initiated Phase-2 study, MO-Ped Trial, evaluating the safety and efficacy of the Company’s lead product candidate palovarotene for the treatment of pediatric patients with multiple osteochondromas (MO), also known as multiple hereditary exostoses (MHE). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Ovid Therapeutics Inc. (NASDAQ: OVID), which also belongs to the Healthcare sector as the Company Clementia Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=OVID

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Clementia Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CMTA

MO-Ped Trial is First-ever Clinical Trial of an Investigational Agent for Treatment of MO

Clarissa Desjardins, Ph.D., Chief Executive Officer of Clementia, stated that the initiation of the MO-Ped Trial marks the second global, late-stage study now underway for palovarotene. This trial is the first-ever clinical trial of an investigational agent for the treatment of MO. Clarissa added that Palovarotene’s mechanism of action, which is to inhibit BMP signaling, along with its promising preclinical data and favorable tolerability profile in clinical studies, gives hope that this could be the first safe and effective treatment for MO.

The Phase-2 MO-Ped Trial

The MO-Ped Trial will enroll 240 patients ranging in age from 2 to 14 years old at approximately 29 centers in 12 countries around the world. Patients enrolled will be randomized into one of three arms to receive a weight adjusted equivalent of 2.5 mg or 5.0 mg of palovarotene daily, or placebo. The primary efficacy endpoint of the trial is the rate of new osteochondromas (OCs) in the two treatment groups as assessed by whole body MRI, versus the placebo control group. Secondary endpoints include the change in the total volume of OCs, the rate of new or worsening deformities and the rate of MO-related surgeries. Enrolled patients will be treated for 24 months. Clementia expects the 12-month interim data readout to be in the first half of 2020, with 24-month top-line results from the study in the first half of 2021.

Clementia Initiated Phase-3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

In December 2017, the Company commenced the MOVE Trial, its Phase-3 registration study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP). The MOVE Trial will be conducted at approximately 20 centers in 16 countries around the world. Completion of enrollment in the trial is expected by the end of 2018. FOP is a rare, severely disabling disorder characterized by heterotopic ossification (HO), or bone that forms outside the normal skeleton in muscles, tendons or soft tissue.

About Multiple Osteochondromas

MO, also called multiple hereditary exostoses, or MHE, is an ultra-rare, severely disabling, progressive, chronic disease in which multiple benign bone tumors known as OCs, or osteocartilaginous exostoses, develop on bones. MO is typically diagnosed in early childhood when OCs become visible with a median age at diagnosis of four years. These osteochondromas usually continue to grow until shortly after puberty and may lead to bone deformities, skeletal abnormalities, short stature, nerve compression and reduced range of motion. Today, the only available treatments for MO are surgery and palliative care, and many patients will undergo surgery, some as many as 30 surgeries, before adulthood.

About Palovarotene

Palovarotene is an RARγ agonist being developed as a treatment for patients with ultra-rare and debilitating bone diseases, including MO and FOP, as well as other diseases. Palovarotene was found to inhibit the formation of osteochondromas (OCs) in mouse models of MO, supporting the initiation of the MO-Ped Trial in the MO indication. Palovarotene has received Orphan Drug status for FOP and MO from the US Food and Drug Administration (FDA), and orphan status for the treatment of FOP in the EU. In addition, palovarotene has been granted Fast Track and Breakthrough Therapy designations for FOP from the FDA.

Stock Performance Snapshot

April 23, 2018 – At Monday’s closing bell, Clementia Pharma’s stock climbed 10.44%, ending the trading session at $19.47.

Volume traded for the day: 37.62 thousand shares.

Stock performance in the last month – up 14.06%; previous three-month period – up 11.26%; past six-month period – up 21.23%; and year-to-date – up 2.58%

After yesterday’s close, Clementia Pharma’s market cap was at $683.98 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the ”Author”) and is fact checked and reviewed by a third-party research service company (the ”Reviewer”) represented by a credentialed financial analyst. For further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the ”Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 497119